Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Whistleblower sues Eli Lilly over drug manufacturing problems

Published 06/06/2022, 08:22 PM
Updated 06/07/2022, 11:57 AM
© Reuters. FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar/File Photo/File Photo

© Reuters. FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar/File Photo/File Photo

By Dan Levine and Marisa Taylor

(Reuters) -A former human resources officer at Eli Lilly (NYSE:LLY) and Co sued the drugmaker on Monday, alleging she was terminated after pointing out poor manufacturing practices and data falsification involving one of its blockbuster diabetes drugs.

The plaintiff, Amrit Mula, alleges violations of an employee protection law and seeks unspecified damages. The U.S. Department of Justice last year launched a criminal investigation into alleged manufacturing irregularities at an Eli Lilly plant in New Jersey following a Reuters story that detailed some of Mula's allegations.

Lilly in a statement on Tuesday called Mula's allegations "baseless" and said it "looks forward to the opportunity to defend itself in court."

The company also said it "continues to cooperate" with a Justice Department subpoena and to work collaboratively with the U.S. Food and Drug Administration.

Mula said she "made every effort to resolve this controversy and avoid litigation entirely, but unfortunately we were unable to do so."

The Justice Department declined to comment.

An employee at the New Jersey plant starting in 2004, Mula contends in the lawsuit that she repeatedly pressured site leaders starting in 2018 to remedy manufacturing violations involving several biologic drugs, including type 2 diabetes medicine Trulicity.

"Lilly executives responded by marginalizing, harassing and eventually terminating her position under false pretenses," said the lawsuit, filed in a New Jersey federal court.

© Reuters. FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar/File Photo/File Photo

In November 2019, FDA inspectors arrived at the Branchburg plant for an inspection and found that quality control data had been deleted and not appropriately audited.

Federal documents show the FDA cited the problems in 2020 as "Official Action Indicated," or OAI, which is its most serious category of violation. The FDA has not taken further public action and declined to comment on the whistleblower suit.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.